What are the main ophthalmic drug classes and their standard dosing regimens for conditions such as bacterial conjunctivitis, postoperative inflammation, glaucoma, uveitis, and age‑related macular degeneration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Ophthalmic Pharmacology: Drug Classes and Standard Dosing

Bacterial Conjunctivitis

For mild bacterial conjunctivitis, a 5-7 day course of any broad-spectrum topical antibiotic is effective, with selection based on convenience and cost rather than superiority of any specific agent 1. The condition is self-limited in immunocompetent adults, but treatment shortens clinical course by 2-5 days and reduces transmissibility 1.

Mild Cases

  • Any broad-spectrum topical antibiotic for 5-7 days
  • Povidone-iodine 1.25% ophthalmic solution is equally effective when antibiotic access is limited 1
  • Follow-up only if no improvement in 3-4 days

Moderate to Severe Cases (copious purulent discharge, pain, marked inflammation)

  • Obtain conjunctival cultures and Gram stain if gonococcal infection suspected
  • Consider MRSA coverage given increasing community prevalence 1
  • May require compounded vancomycin based on culture results

Gonococcal Conjunctivitis

  • Systemic antibiotics mandatory (see specific protocols) 1
  • Add saline lavage for comfort
  • Daily follow-up until resolution
  • Evaluate for sexual abuse in children

Postoperative Inflammation

Topical NSAIDs are the primary agents for postoperative inflammation following cataract extraction and refractive procedures, with nepafenac 0.1% offering superior corneal penetration 2.

Available NSAIDs

  • Nepafenac 0.1% (prodrug with enhanced posterior segment penetration)
  • Diclofenac
  • Ketorolac
  • Bromfenac
  • Flurbiprofen

Key Applications

  • Prevention of intraoperative miosis
  • Reduction of postoperative pain and inflammation
  • Prevention of cystoid macular edema 2

Critical Safety Considerations

Avoid concurrent use of NSAIDs with topical corticosteroids in the presence of significant pre-existing corneal inflammation—this combination precipitates corneal erosions and melts 3. NSAIDs can cause indolent corneal ulceration, particularly under conditions of corneal hypoxia 3. Use corticosteroids with poor ocular penetration (fluorometholone, loteprednol) to minimize IOP elevation and cataract formation 1.

Glaucoma

The evidence provided focuses primarily on epidemiology rather than specific drug classes and dosing. Based on general ophthalmology knowledge, standard classes include:

Primary Drug Classes

  • Prostaglandin analogs (first-line)
  • Beta-blockers
  • Alpha-2 agonists
  • Carbonic anhydrase inhibitors (topical and systemic)
  • Cholinergic agonists

Note: The provided evidence does not contain specific guideline-based dosing protocols for glaucoma medications.

Uveitis

Topical corticosteroids should be tapered once inflammation is controlled, using the minimum effective dose 1. Site-specific corticosteroids like loteprednol or fluorometholone reduce risk of IOP elevation and cataract formation 1.

Follow-up Protocol

  • Regular monitoring with interval history, visual acuity, IOP measurement, and slit-lamp biomicroscopy
  • Slow taper to minimum effective dose
  • Monitor for recurrence

Viral Conjunctivitis

Adenoviral Conjunctivitis

  • Self-limited; topical corticosteroids reserved for symptomatic subepithelial infiltrates causing blurring, photophobia, or decreased vision 1
  • Taper corticosteroids once controlled
  • Cyclosporine 0.05% to 1% is an effective alternative for reducing subepithelial infiltrates 1
  • Subepithelial infiltrates typically appear ≥1 week after onset

Herpes Simplex Virus Conjunctivitis

Topical ganciclovir 0.15% gel 3-5 times daily is preferred over trifluridine due to lower epithelial toxicity 1.

Topical Options

  • Ganciclovir 0.15% gel: 3-5 times daily (less toxic) 1
  • Trifluridine 1%: 5-8 times daily (causes inevitable epithelial toxicity if used >2 weeks) 1

Oral Options

  • Acyclovir: 200-400 mg five times daily
  • Valacyclovir: 500 mg 2-3 times daily
  • Famciclovir: 250 mg twice daily 1

Critical: Topical corticosteroids potentiate HSV epithelial infections and must be avoided 1. Oral antivirals alone may be inadequate for HSV blepharoconjunctivitis; add topical antiviral treatment 1.

Varicella Zoster Virus Conjunctivitis

For persistent or recalcitrant acute/subacute disease in immunocompetent patients, use oral antivirals 1:

  • Acyclovir: 800 mg five times daily for 7 days
  • Valacyclovir: 1000 mg every 8 hours for 7 days
  • Famciclovir: 500 mg three times daily for 7 days

Topical antivirals alone are not helpful but may be added in unresponsive cases 1. Topical antibiotics prevent secondary bacterial infection of vesicles 1.

Molluscum Contagiosum

  • Treatment requires physical removal: incision and curettage (with bleeding), excision, excision with cautery, or cryotherapy 1
  • Conjunctivitis may take weeks to resolve after lesion elimination
  • Multiple/large lesions in adults suggest immunocompromise

Age-Related Macular Degeneration

Anti-VEGF therapy should be initiated immediately upon diagnosis of neovascular AMD, as treatment within 2 years reduces legal blindness and visual impairment 4.

Prevention (Intermediate AMD or Monocular Advanced AMD)

  • AREDS2 formulation: vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin 4
  • Approximately 8 million Americans ≥55 years are candidates
  • Could prevent progression in >300,000 patients 4

Modifiable Risk Factors

  • Smoking cessation (strongest modifiable risk factor—risk increases with pack-years) 4
  • Mediterranean-style diet 5
  • Regular exercise 5
  • Management of hypertension and dyslipidemia 6

Treatment of Neovascular AMD

  • Intravitreal anti-VEGF therapy remains the mainstay 5
  • Standard of care is immediate treatment upon diagnosis 4
  • Early treatment (within 2 years) associated with more favorable prognosis 4

Emerging Therapies

  • Complement inhibitors for geographic atrophy 5
  • Gene therapy, sustained-delivery systems, and laser therapies under investigation 5

Key Clinical Pitfalls

  1. Never combine topical NSAIDs with corticosteroids in the presence of significant corneal inflammation—this precipitates corneal melts 3

  2. Never use topical corticosteroids in HSV conjunctivitis—they potentiate epithelial infection 1

  3. Trifluridine causes inevitable epithelial toxicity after 2 weeks—use ganciclovir for longer courses 1

  4. Gonococcal conjunctivitis requires systemic antibiotics—topical therapy alone is inadequate 1

  5. AMD treatment must begin immediately upon diagnosis—delays worsen prognosis 4

References

5
Research

Age-related macular degeneration: Updates for general practitioners.

Australian journal of general practice, 2026

Related Questions

In a patient with age‑related macular degeneration (AMD) and glaucoma who has experienced a decline in visual acuity from 6/40 to 6/30, what management steps should be taken?
What are the treatment options for age‑related macular degeneration (ARMD), including management of dry (non‑neovascular) and wet (neovascular) forms?
What medication is appropriate for right eye swelling and excessive tearing?
In a 52‑year‑old patient with visual symptoms that could be due to age‑related macular degeneration, what does the ophthalmologist mean by degeneration of the crystalline lens, and how should it be evaluated and managed?
What are the primary pharmacologic classes in ophthalmology and representative drugs, including typical concentrations, routes, dosing schedules, and common indications?
How should mild hydronephrosis be managed and followed up?
How can a child develop an acute varicella infection despite having received varicella vaccination?
What is mild hydronephrosis?
What infusion rate in mL per hour should be set for a 10% dextrose (D10) solution to deliver 4 g of dextrose per hour?
What are the primary pharmacologic classes in ophthalmology and representative drugs, including typical concentrations, routes, dosing schedules, and common indications?
Can you provide a concise summary of the article "Emerging Role of Electroencephalographic Aperiodic Activity in Anesthesia: A Narrative Review"?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.